Is Royalty Pharma plc overvalued?

Royalty Pharma plc (RPRX) looks overvalued — trading about 55% above its fair value.

Overvalued

Price

$59.22

Fair value

$26.85

Current P/E

32.9

Normal P/E

14.9

Market cap

$26.25B

Dividend yield

1.6%

Return on equity

12.3%

Sector

Healthcare

Fair value compares RPRX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks